Trial
NCT01738698
Adjunctive SPD489 to Antipsychotic Medication in Clinically Stable Adults With Persistent Predominant Negative Symptoms of Schizophrenia
Phase IIITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Shire
Collaborators
—
Condition
Schizophrenia
Intervention
SPD489 40mg
Why stopped
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-06-22